Bowen's Disease - Market Insight, Epidemiology, and Market Forecast - 2034

Key Highlights

• The Bowen’s disease market is anticipated to sustain a steady Compound Annual Growth Rate (CAGR) during the forecast period (2025-2034). This growth in market revenue is primarily propelled by an aging global population leading to higher disease incidence, increased cumulative ultraviolet radiation exposure, the development and uptake of novel topical and minimally invasive therapies, and improved reimbursement policies facilitating broader treatment access.
• The increasing cases of Bowen’s disease may be attributed to greater clinician and patient awareness resulting in more frequent screenings, enhanced diagnostic sensitivity through widespread use of dermoscopy and biopsy, rising ultraviolet light exposure from lifestyle and environmental factors, and a growing population of immunocompromised individuals.
• The Bowen’s disease market is dominated by low-cost, off-patent local therapies - topical 5-fluorouracil, imiquimod, diclofenac gel, cryotherapy, photodynamic therapy, and surgical excision - that lack systemic activity or molecular specificity, limiting both clinical differentiation and pricing power.
• Sirnaomics’ STP705, a polypeptide nanoparticle-delivered dual Transforming Growth Factor beta 1 (TGF-β1)/Cyclooxygenase-2 (COX-2) RNA interference therapeutic in late-stage clinical development, represents the sole truly novel, targeted candidate; its potential to offer systemic and mechanism-focused intervention is poised to disrupt the current paradigm and drive market growth through 2034.

The comprehensive report titled “Bowen’s Disease - Market Insights, Epidemiology, and Market Forecast - 2034” offers a detailed analysis of Bowen’s disease. The report presents historical and projected epidemiological data covering total incident cases of Bowen’s disease, gender-specific incident cases of Bowen’s disease, site-specific incident cases of Bowen’s disease, and treated cases of Bowen’s disease. In addition to epidemiology, the market report encompasses various aspects related to the patient population. These aspects include the diagnosis process, prescription patterns, physician perspectives, market accessibility, treatment options, and prospective developments in the market across seven major markets: the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, spanning from 2020 to 2034.

The report analyzes the existing treatment practices and unmet medical requirements in Bowen’s disease. It evaluates the market potential and identifies potential business prospects for enhancing therapies or interventions. This valuable information enables stakeholders to make well-informed decisions regarding product development and strategic planning for the market.

Bowen’s Disease Overview

Bowen’s disease is an in-situ squamous cell carcinoma confined to the epidermis and represents an early stage of skin cancer with a slow-growing clinical course. It most often occurs on sun-exposed areas such as the lower legs, face, and neck, particularly in fair-skinned individuals, but it can also develop in non-sun-exposed and mucosal sites, including the genitalia. The condition is typically characterized by a well-defined, scaly or crusted erythematous patch that may be flat or slightly raised. The etiology is multifactorial, with key contributors including chronic ultraviolet radiation exposure, human papillomavirus infection, and immunosuppression. Though generally indolent, Bowen’s disease carries a small but notable risk of progression to invasive squamous cell carcinoma if left unrecognized or untreated.

Bowen’s Disease Diagnosis and Treatment Algorithm

The diagnosis of Bowen’s disease requires histopathological confirmation through a skin biopsy, which typically reveals full-thickness atypia of the epidermis without invasion into the dermis. Key microscopic features include disordered keratinocyte maturation, nuclear atypia throughout the epidermis, hyperkeratosis, and parakeratosis. While non-invasive tools such as dermoscopy and reflectance confocal microscopy can aid in clinical evaluation by highlighting vascular patterns and cellular abnormalities, they are adjunctive and not diagnostic. A definitive diagnosis hinges on biopsy-proven evidence of intraepidermal squamous neoplasia without dermal involvement.

Treatment of Bowen’s disease involves a range of effective options tailored to the lesion’s location, size, and patient-specific factors. Common modalities include topical therapies such as imiquimod or 5-fluorouracil, cryotherapy with liquid nitrogen, surgical excision, curettage with cautery, and photodynamic therapy using a light-sensitive agent and targeted illumination. In select cases, radiotherapy or laser ablation may also be employed. Given its superficial nature and slow progression, Bowen’s disease carries a high cure rate with appropriate intervention, and close clinical monitoring may suffice when treatment risks outweigh benefits.

Bowen’s Disease Epidemiology

The epidemiology section of the Bowen’s disease market report offers information on the patient populations, including historical and projected trends for each of the seven major markets. Examining key opinion leader views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The diagnosed patient pool, their trends, and the underlying assumptions are all included in this section of the report.

This section also presents the data with relevant tables and graphs, offering a clear and concise view of the incidence of Bowen’s disease. Additionally, the report discloses the assumptions made during the analysis, ensuring data interpretation and presentation transparency. This epidemiological data is valuable for understanding the disease burden and its impact on the patient population across various regions.

Key Findings

In Italy, the anatomical distribution of Bowen’s disease differs between sexes. In males, the most commonly affected site is the head and neck at 31%, followed by the lower limbs at 24%, trunk at 21%, upper limbs at 15%, and acral sites at 9%. In females, the lower limbs are the most frequently involved site at 39%, followed by the trunk at 24%, head and neck at 17%, upper limbs at 14%, and acral sites at 6%.

In the UK, Bowen’s disease occurs at an estimated rate of 15 per 100,000 people each year, with higher incidence in areas of greater sun exposure. It is more commonly diagnosed in women, who account for approximately 70-85% of cases, and typically presents between the ages of 60 and 70.

In Japan, among patients diagnosed with skin cancer, squamous cell carcinoma accounted for 43.9%, with 18.3% of these cases identified as in situ squamous cell carcinoma.

The epidemiology of Bowen’s disease is expected to change during the forecast period (2025-2034).

Bowen’s Disease Market Outlook

The Bowen’s disease therapeutics market is further expected to increase by the major drivers, such as the rising incidence population, technological advancements, and upcoming therapies in the forecast period (2025-2034).

With ongoing research and continued dedication, the future holds hope for even more effective treatments and, ultimately, a cure for this challenging condition. According to the publisher, the Bowen’s disease market in the 7MM is expected to change significantly during the forecast period 2025-2034.

Bowen’s Disease Drug Chapters

Emerging Bowen’s Disease Drugs

The Bowen’s disease market is expected to evolve gradually, driven by the limited number of emerging therapies currently in development. Key players such as STP705, among others are showing active commitment to addressing this unmet need, with ongoing efforts to advance novel treatment options for this complex condition.

STP705: Sirnaomics

STP705, a small interfering RNA (siRNA)-based therapeutic that inhibits TGF-β1 and COX-2, is in late-stage clinical development for squamous cell carcinoma in situ. It is delivered using Sirnaomics’ proprietary polypeptide nanoparticle (PNP) RNA interference (RNAi) delivery platform, specifically formulated for intratumoral administration (PNP-IT). By targeting two key pathways involved in oncogenesis and fibrosis, STP705 offers a novel therapeutic approach for this indication and holds global commercial rights.

In June 2023, Sirnaomics advanced STP705 into late-stage clinical development for squamous cell carcinoma in situ following an End-of-Phase II meeting with the US FDA. The decision was supported by positive Phase IIa and IIb results. The FDA provided guidance to proceed based on the demonstrated efficacy of STP705.

In December 2022, Sirnaomics announced positive interim results from part one of its ongoing Phase IIb trial evaluating STP705 in adults with cutaneous squamous cell carcinoma in situ. The dose-escalation study assessed intralesional administration of STP705, a dual-targeted siRNA therapeutic delivered via polypeptide nanoparticles. Interim findings showed that 78% of the 32 treated patients achieved histological clearance, with one cohort reaching 89% clearance.

vBowen’s Disease Market Segmentation

The ‘Bowen’s Disease - Market Insights, Epidemiology, and Market Forecast - 2034’ report provides a detailed outlook of the current and future Bowen’s disease market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies.

Bowen’s Disease Market Size by Countries

The Bowen’s disease market size is assessed separately for various countries, including the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. In 2024, the United States held a significant share of the overall 7MM (Seven Major Markets) Bowen’s disease market, primarily attributed to the country’s higher incidence of the condition and the elevated cost of the available treatments. This dominance is projected to persist, especially with the potential early introduction of new products.

Bowen’s Disease Drugs Uptake

This section focuses on the sales uptake of potential Bowen’s disease drugs that have recently been launched or are anticipated to be launched in the Bowen’s disease market between 2020 and 2034. It estimates the market penetration of Bowen’s disease drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the Bowen’s disease market.

The emerging Bowen’s disease therapies are analyzed based on various attributes such as safety and efficacy in randomized clinical trials, order of entry and other market dynamics, and the unmet need they fulfill in the Bowen’s disease market.

Bowen’s Disease Market Access and Reimbursement

The ‘Bowen’s Disease - Market Insights, Epidemiology, and Market Forecast - 2034’ report provides a descriptive overview of the market access and reimbursement scenario of Bowen’s disease.

This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments.

KOL Views

To keep up with current Bowen’s disease market trends and fill gaps in secondary findings, we interview KOLs and SMEs’ working in the Bowen’s disease domain. Their opinion helps understand and validate current and emerging therapies and treatment patterns or Bowen’s disease market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the Bowen’s disease unmet needs.

Bowen’s Disease: KOL Insights

The analysts connected with 30+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as Massachusetts General Hospital, US, University of Mainz, Germany, University of Barcelona, Barcelona, Spain, ellvitge-Idibell University Hospital, Barcelona, Spain, University of Leeds, Leeds, UK, and Juntendo University School of Medicine, Japan, among others.
“Bowen’s disease typically presents as red, scaly patches that may resemble raised spots or warts, with the affected skin often appearing inflamed or sore. While commonly asymptomatic apart from the visible lesion, some patients experience itching, bleeding, or localized discomfort. In genital presentations - such as Bowenoid papulosis - the lesions tend to appear as brown or dark brown patches on the pubic or genital area. When affecting the vulva or oral mucosa, white patches known as leukoplakia may be observed, highlighting the variable morphology based on anatomical site.”
“The exact cause of Bowen’s disease is often unclear, but prolonged exposure to ultraviolet radiation from sunlight or sunbeds is a major risk factor. Its occurrence on sun-protected areas, however, suggests additional etiologies. Immunosuppression - whether due to conditions like AIDS or immunosuppressive therapy post-transplant - increases susceptibility. A specific form, bowenoid papulosis, is strongly linked to human papillomavirus type 16, a virus also implicated in anogenital cancers. Chronic arsenic exposure, particularly through contaminated drinking water, is another recognized but less common contributing factor, underscoring the multifactorial nature of the disease.”
“Cryotherapy with liquid nitrogen is a commonly used, low-cost treatment for Bowen’s disease, particularly effective for small, well-located lesions. Outcomes vary depending on technique, lesion size, and freeze-thaw cycle duration, with longer or repeated cycles offering better clearance but higher risk of delayed healing and cosmetic changes. While generally effective, cryotherapy may be less favorable than photodynamic therapy in terms of ulceration risk and overall clearance in some cases.”

Competitive Intelligence Analysis

We conduct a Competitive and Market Intelligence analysis of the Bowen’s disease Market, utilizing various Competitive Intelligence tools such as SWOT analysis and Market entry strategies. The inclusion of these analyses is contingent upon data availability, ensuring a comprehensive and well-informed assessment of the market landscape and competitive dynamics.

Bowen’s Disease Pipeline Development Activities

The report offers an analysis of therapeutic candidates in Phase II and III stages and examines companies involved in developing targeted therapeutics for Bowen’s disease. It provides valuable insights into the advancements and progress of potential treatments in clinical development for this condition.

Pipeline Development Activities

The report covers information on collaborations, acquisition and merger, licensing, patent details, and other information for emerging Bowen’s disease therapies.

Bowen’s Disease Report Insights

• Bowen’s Disease Patient Population
• Therapeutic Approaches
• Bowen’s Disease Pipeline Analysis
• Bowen’s Disease Market Size and Trends
• Bowen’s Disease Market Opportunities
• Impact of Upcoming Therapies

Bowen’s Disease Report Key Strengths

• 10 Years Forecast
• The 7MM Coverage
• Bowen’s Disease Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Bowen’s Disease Market
• Bowen’s Disease Drugs Uptake

Bowen’s Disease Report Assessment

• Bowen’s Disease Current Treatment Practices
• Unmet Needs
• Bowen’s Disease Pipeline Product Profiles
• Bowen’s Disease Market Attractiveness

Key Questions

• How common is Bowen’s disease?
• What are the key findings of Bowen’s disease epidemiology across the 7MM, and which country will have the highest number of patients during the study period (2020-2034)?
• What are the currently available treatments for Bowen’s disease?
• What are the disease risk, burden, and unmet needs of Bowen’s disease?
• At what CAGR is the Bowen’s disease market and its epidemiology is expected to grow in the 7MM during the forecast period (2025-2034)?
• How would the unmet needs impact the Bowen’s disease market dynamics and subsequently influence the analysis of the related trends?
• What would be the forecasted patient pool of Bowen’s disease in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
• Among EU4 and the UK, which country will have the highest number of patients during the forecast period (2025-2034)?
• How many companies are currently developing therapies for the treatment of Bowen’s disease?

Reasons to buy

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Bowen’s disease Market.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of current treatment in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
• To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

This product will be updated with the latest data at the time of order. Consequently, dispatch time for this product will be 7-10 business days.